National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 14 of 1992)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, serves as a foundational piece of legislation aimed at establishing and maintaining standards of health across the nation. This Act provides the framework for various health-related initiatives, including the Pharmaceutical Benefits Scheme (PBS). The gap it was introduced to address was the need for a structured and equitable system to ensure that essential medications are accessible and affordable to all Australians. In 1992, a legislative instrument was issued under the authority of the Act to refine the scope of the PBS. The policy objective of this instrument was to adjust the list of subsidised pharmaceuticals by removing certain drugs and medicinal preparations from the PBS to ensure that resources are allocated efficiently and only to those treatments that continue to meet the required standards of efficacy and necessity. This legislative instrument, declared by David Trevor Graham as the Assistant Secretary of the Pharmaceutical Benefits Branch, effectively ceased the subsidy of specific drugs including Acrylic Resin, Iron Dextran, and Levodopa, reflecting an ongoing evaluation and adjustment of the PBS to align with public health priorities.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the National Health Act 1953 applies to specific drugs and medicinal preparations listed in the Schedule, thereby removing them from the scope of Part VII of the Act. This legislation affects entities and individuals involved in the pharmaceutical industry, particularly those engaged in the supply, manufacturing, or distribution of the specified medications. The Act operates on a national level as it is a Commonwealth legislation, ensuring uniformity across Australia in terms of the pharmaceutical benefits scheme. This particular legislative instrument excludes the mentioned drugs and preparations from the benefits provided under the National Health Act 1953, impacting the eligibility for subsidies and coverage for these specific medications. The exclusions are effective from 1 December 1992, as stipulated in the Declaration, and any further adjustments or additions to the scope of this Act may be made through subordinate instruments or subsequent legislative updates.

Key Provisions

The National Health Act 1953, in the context of the Pharmaceutical Benefits Declaration under subsection 85(2AA), specifies certain drugs and medicinal preparations that will no longer be subject to Part VII of the Act. This legislative instrument, numbered PB 14 of 1992, made by David Trevor Graham, an Assistant Secretary within the Pharmaceutical Benefits Branch of the Department of Health, Housing and Community Services, and acting as a delegate for the Minister, clarifies which pharmaceutical products are excluded from the benefits scheme. According to section 1 of the Declaration, these changes took effect from 1 December 1992. The specific substances mentioned in the Schedule, namely Acrylic Resin, Iron Dextran, and Levodopa, are the ones that are removed from the list of drugs and medicinal preparations covered under Part VII of the National Health Act 1953 (sections 1 and 2). The Declaration imposes obligations on the relevant parties to ensure compliance with the changes outlined in the legislative instrument. It mandates that these specific drugs and preparations are no longer considered under the Pharmaceutical Benefits Scheme, thus altering their status within the healthcare system. The entities involved, including healthcare providers and patients, must adhere to this new legislative framework, recognising that the specified drugs are no longer eligible for the benefits previously provided under the Act. The Pharmaceutical Benefits Advisory Committee's advice, referenced in subsection 85(2AB) of the National Health Act 1953, underpins the rationale behind these changes, ensuring that the decision to exclude these substances is informed and justified. The legislation does not explicitly outline specific offences, penalties, or consequences for breaches in this context. However, non-compliance with the Act's provisions, including the exclusion of specified drugs from the Pharmaceutical Benefits Scheme, could potentially lead to legal repercussions. Parties failing to adhere to the changes may face administrative actions or legal challenges, as the Act's overarching purpose is to regulate and manage the healthcare system effectively. The precise legal consequences would depend on the nature and extent of the non-compliance, as well as the specific provisions of the National Health Act 1953 that are relevant to the situation at hand.